Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).

PubMed  Article  Google Scholar 

Abeshouse, A. et al. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).

CAS  Article  Google Scholar 

Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rencsok, E. M. et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol. Biomark. Prev. 29, 1374–1380 (2020).

Article  Google Scholar 

Hooker, S. E. et al. Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines. Cancer Epidemiol. Biomark. Prev. 28, 1003–1009 (2019).

CAS  Article  Google Scholar 

Mersha, T. B. & Abebe, T. Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum. Genomics 9, 1 (2015).

PubMed  PubMed Central  Article  Google Scholar 

Banda, Y. et al. Characterizing race/ethnicity and genetic ancestry for 100,000 subjects in the genetic epidemiology research on adult health and aging (GERA) cohort. Genetics 200, 1285–1295 (2015).

PubMed  PubMed Central  Article  Google Scholar 

Stopsack, K. H. et al. Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-2577 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Sivakumar, S. et al. Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: a large-scale analysis. J. Clin. Oncol. 39, 5003–5003 (2021).

Article  Google Scholar 

Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93–99 (2020).

CAS  PubMed  Article  Google Scholar 

Koga, Y. et al. Genomic profiling of prostate cancers from men with African and European ancestry. Clin. Cancer Res. 26, 4651–4660 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Shoag, J. & Barbieri, C. Clinical variability and molecular heterogeneity in prostate cancer. Asian J. Androl. 18, 543 (2016).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).

CAS  PubMed  Article  Google Scholar 

Brenner, J. C., Chinnaiyan, A. M. & Tomlins, S. A. ETS Fusion Genes in Prostate Cancer. Prostate Cancer: Biochemistry, Molecular Biology and Genetics (Springer New York, 2013).

Tomlins, S. A. et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 56, 275–286 (2009).

CAS  PubMed  Article  Google Scholar 

Mehra, R. et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Attard, G. et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912–2918 (2009).

CAS  PubMed  Article  Google Scholar 

Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006).

CAS  PubMed  Article  Google Scholar 

Pettersson, A. et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol. Biomark. Prev. 21, 1497–1509 (2012).

Article  Google Scholar 

Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006).

CAS  PubMed  Article  Google Scholar 

Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73–80 (2008).

CAS  PubMed  Article  Google Scholar 

Paulo, P. et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 51, 2430–249 (2012).

Article  CAS  Google Scholar 

Magi-Galluzzi, C. et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71, 489–497 (2011).

CAS  PubMed  Article  Google Scholar 

Minner, S. et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 17, 5878–5888 (2011).

CAS  PubMed  Article  Google Scholar 

Park, K. et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590–IN21 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schumacher, F. R. et al. Race and genetic alterations in prostate cancer. JCO Precis. Oncol. https://doi.org/10.1200/PO.21.00324 (2021).

Article  PubMed  Google Scholar 

Park, K. et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 32, 206–211 (2014).

PubMed  Article  Google Scholar 

Taneja, S. S. et al. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J. Clin. Oncol. 31, 523–529 (2013).

CAS  PubMed  Article  Google Scholar 

Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596–4599 (2007).

CAS  PubMed  Article  Google Scholar 

Attard, G. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253–263 (2008).

CAS  PubMed  Article  Google Scholar 

Gopalan, A. et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 69, 1400–1406 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Swanson, T. A. et al. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate 71, 1548–1558 (2011).

CAS  PubMed  Article  Google Scholar 

Mani, R.-S. et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326, 1230–1230 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dal Pra, A. et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin. Cancer Res. 19, 5202–5209 (2013).

CAS  PubMed  Article  Google Scholar 

Song, C. & Chen, H. Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis. Cancer Cell Int. 18, 177 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Khani, F. et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin. Cancer Res. 20, 4925–4934 (2014).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mahal, B. A. et al. Racial differences in genomic profiling of prostate cancer. N. Engl. J. Med. 383, 1083–1085 (2020).

PubMed  PubMed Central  Article  Google Scholar 

Petrovics, G. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005).

CAS  PubMed  Article  Google Scholar 

Rosen, P. et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 80, 749–753 (2012).

PubMed  Article  Google Scholar 

Farrell, J. et al. Predominance of ERG-negative high-grade prostate cancers in African American men. Mol. Clin. Oncol. 2, 982–986 (2014).

PubMed  PubMed Central  Article  Google Scholar 

Faisal, F. A. et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor